8-K 申報｜Microbot Medical Inc.（納斯達克代碼：MBOT）

false
 0000883975
 
 
 
 
 
 
 
 0000883975
 
 
 2026-05-14
 2026-05-14
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

FORM
8-K

 

CURRENT
REPORT

Pursuant
to Section 13 or 15(d)

of
the Securities Exchange Act of 1934

 

Date
of Report (Date of earliest event reported): May 14, 2026

 

MICROBOT
MEDICAL INC.

(Exact
name of registrant as specified in its charter)

 

 
 Delaware
  
 000-19871
  
 94-3078125

 
 (State
 or other jurisdiction

 of
 incorporation)

  
 (Commission

 File
 Number)

  
 (IRS
 Employer

 Identification
 No.)

 
 

175
Derby St., Bld. 27

Hingham,
MA 02043

(Address
of Principal Executive Offices) (Zip Code)

 

Registrant’s
telephone number, including area code: (781) 875-3605

 

 

(Former
Name or Former Address, if Changed Since Last Report)

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

 

 
 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 
 Common
 Stock, $0.01 par value
  
 MBOT
  
 NASDAQ
 Capital Market

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging
Growth Company ☐

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

  

 

 

Item
7.01 Regulation FD Disclosure.

 

On
May 14, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it recorded revenue resulting
from its limited market release of the LIBERTY® Endovascular Robotic System during the first quarter of 2026, and that
the Company’s recent transition to the full market release has resulted in increased revenue for the second quarter of 2026, which
has already exceeded Q1 revenue, as utilization and adoption of the LIBERTY System accelerates across multiple sales territories.

 

The
press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information
in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be
deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

 

Item
8.01 Other Events.

 

On
May 14, 2026, the Company announced that it recorded revenue resulting from its limited market release of the LIBERTY®
Endovascular Robotic System during the first quarter of 2026, and that the Company’s recent transition to the full market release
has resulted in increased revenue for the second quarter of 2026, which has already exceeded Q1 revenue, as utilization and adoption
of the LIBERTY System accelerates across multiple sales territories.

 

Forward
Looking Statements

 

This
Item 8.01 of this Current Report on Form 8-K may contain “forward-looking statements.” Such statements which are not purely
historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “intends,” “would,” “could” and “estimates”)
are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future,
including but not limited to, regulatory milestones.

 

Actual
results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements
are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although
the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no
assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information
set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from
time-to-time with the Securities and Exchange Commission.

 

Item
9.01. Financial Statements and Exhibits.

 

(d)
Exhibits

 

 
 Exhibit

 Number
  
 Description

 
  
  
  

 
 99.1
  
 Press Release

 
 104
  
 Cover
 Page Interactive Data File (embedded within the Inline XBRL document)

 
 

   

  

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.

 

 
  
 MICROBOT
 MEDICAL INC.

 
  
  

 
  
 By:
 /s/
 Harel Gadot

 
  
 Name:
 Harel
 Gadot

 
  
 Title:
 Chief
 Executive Officer, President and Chairman

 
 

Date:
May 14, 2026